US Edition
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
AbbVie’s $195 million investment expands API production for neuroscience, immunology, and oncology medicines while supporting over 6,000 American pharmaceutical manufacturing jobs.
- AbbVie announced a $195 million investment at its North Chicago facility, supporting API production and job creation, as part of its US investment plan.
- Given recent disruptions to pharmaceutical supply chains, AbbVie’s expansion at its North Chicago facility addresses supply chain security and enhances resilience.
- Over 6,000 American jobs are supported by AbbVie's U.S. manufacturing, and the facility will expand chemical synthesis capabilities for neuroscience, immunology and oncology medicines.
- By tapping Illinois Department of Commerce benefits, the project qualifies for incentives and commits to creating at least 50 full-time jobs within three years.
- AbbVie announced that over the next decade, it will expand production of API, drug product, peptides, and medical devices in the U.S. to support future medical breakthroughs.
23 Articles
23 Articles
AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients
Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago, Illinois. AbbvVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox. The new facility will be used for the production of activ…
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next…
AbbVie Invests $195 Million to Expand North Chicago Manufacturing Facility
AbbVie is investing $195 million to strengthen its domestic active pharmaceutical ingredient (API) production within the U.S., with the expansion of its manufacturing plant in North Chicago. This development is part of a larger commitment to invest more than $10 billion in U.S. capital for innovation and critical manufacturing capacity enhancement, according to the company. AbbVie aims to enhance its chemical synthesis capabilities in the countr…
AbbVie Invests $195 Million to Expand Stateside API Manufacturing
The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology, neuroscience, and oncology therapies, reinforcing US pharmaceutical capacity amid industry reshoring and tariff concerns.
Coverage Details
Bias Distribution
- 89% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
